Loqtorzi Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Loqtorzi market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to factors such as an increase in the number of clinics, rising demand for effective treatment options, the growing prevalence of smoking, higher healthcare investments, and the increasing adoption of immunotherapy.

Growth during the market's forecast period will be driven by the increasing burden of cancer, heightened awareness of diagnosis and treatment, rising prevalence of nasopharyngeal cancer, the growing use of combination therapies, and a stronger focus on early detection and prevention. Key trends in the forecast period include advancements in diagnostic techniques, innovations in treatment modalities, development of novel drug formulations, improvements in radiation therapy, and progress in precision medicine.

The increasing prevalence of nasopharyngeal carcinoma (NPC) is expected to drive the growth of the loqtorzi market in the coming years. NPC is a type of cancer affecting the nasopharynx, strongly associated with Epstein-Barr virus infection, where early detection plays a crucial role in treatment success. The rise in NPC prevalence can be attributed to factors such as greater exposure to Epstein-Barr virus, genetic predisposition, environmental influences such as tobacco and alcohol use, and dietary habits, particularly the consumption of salted and preserved foods. Loqtorzi (toripalimab) assists NPC patients by boosting the immune system’s ability to attack cancer cells by inhibiting the PD-1 pathway, providing a new treatment option for recurrent or metastatic NPC, either in combination with chemotherapy or as a monotherapy after disease progression. For example, in 2022, the World Cancer Research Fund reported over 120,434 new NPC cases worldwide. Hence, the increasing prevalence of NPC is fueling the growth of the loqtorzi market.

A key trend in the loqtorzi market is the development of biosimilars to broaden its portfolio and provide cost-effective alternatives to biologic therapies. Biosimilars are biologic products that closely resemble an approved reference product, with no clinically significant differences in safety or efficacy. They offer an affordable option once the original product's patent expires. For instance, in November 2024, Dr. Reddy’s Laboratories, an India-based pharmaceutical company, launched a biosimilar of Coherus BioSciences’ Loqtorzi (toripalimab) in India under the brand name Zytorvi. This drug is approved for treating adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC). Loqtorzi was FDA-approved in October 2023 for first-line treatment of RM-NPC in combination with cisplatin and gemcitabine, as well as a monotherapy for patients with disease progression after platinum-based chemotherapy. It is the only FDA-approved immuno-oncology drug for this indication.

In January 2024, Inovio Pharmaceuticals Inc., a US-based biotech company, entered into a partnership with Coherus BioSciences Inc. This collaboration aims to advance the development of INO-3112 combined with Loqtorzi (toripalimab-tpzi) for treating patients with locoregionally advanced, high-risk, HPV16/18-positive oropharyngeal squamous cell carcinoma (OPSCC), a common form of throat cancer. The partnership leverages the unique mechanisms of both therapies to improve clinical outcomes for patients with this type of cancer. Coherus BioSciences Inc. is a US-based biotech firm developing loqtorzi.

Major players in the loqtorzi market are Coherus BioSciences Inc. and Shanghai Junshi Biosciences Co. Ltd.

North America was the largest region in the loqtorzi market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in loqtorzi report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the loqtorzi market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Loqtorzi (toripalimab-tpzi) is a PD-1 inhibitor biologic drug used to treat nasopharyngeal carcinoma (NPC), especially in cases that are metastatic or recurrent. It works by enhancing the immune system's ability to target and destroy cancer cells through the blocking of the PD-1 receptor on T-cells.

The main formulations available in the loqtorzi market include injectable formulation (intravenous) and lyophilized powder for reconstitution. The injectable formulation refers to the intravenous (IV) administration of toripalimab (Loqtorzi), a monoclonal antibody primarily used for treating various cancers, including small cell lung cancer (SCLC) and nasopharyngeal carcinoma. Indications for Loqtorzi include the treatment of small cell lung cancer (SCLC) and other solid tumors. The patient population includes adults, geriatric patients, and pediatric patients. Distribution occurs through multiple channels, such as direct sales, wholesalers, distributors, retail pharmacies, and online pharmacies. End users of loqtorzi include hospitals, oncology clinics, specialty pharmacies, and research institutions.

The loqtorzi market research report is one of a series of new reports that provides loqtorzi market statistics, including the loqtorzi industry global market size, regional shares, competitors with the loqtorzi market share, detailed loqtorzi market segments, market trends, and opportunities, and any further data you may need to thrive in the loqtorzi industry. This loqtorzi market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The loqtorzi market consists of sales of diagnostic kits, biomarker assays, companion diagnostics, Loqtorzi-related drug delivery systems, and post-treatment care products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.